Newman Dignan & Sheerar’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.21M Hold
1,043
– – 0.23% 80
2026
Q2
$1.25M Buy
1,043
+8
+0.8% +$8.17K 0.24% 73
2026
Q1
$952K Buy
1,035
+19
+2% +$19.3K 0.2% 85
2025
Q4
$1.09M Hold
1,016
– – 0.23% 78
2025
Q3
$775K Sell
1,016
-10
-1% -$7.44K 0.17% 100
2025
Q2
$800K Sell
1,026
-179
-15% -$139K 0.18% 94
2025
Q1
$995K Sell
1,205
-114
-9% -$94.9K 0.27% 77
2024
Q4
$1.02M Sell
1,319
-8
-0.6% -$6.62K 0.26% 77
2024
Q3
$1.19M Sell
1,327
-32
-2% -$28.8K 0.28% 74
2024
Q2
$1.23M Sell
1,359
-36
-3% -$28.8K 0.32% 75
2024
Q1
$1.09M Sell
1,395
-85
-6% -$60.5K 0.29% 83
2023
Q4
$863K Buy
1,480
+100
+7% +$58.4K 0.26% 89
2023
Q3
$741K Hold
1,380
– – 0.24% 91
2023
Q2
$647K Hold
1,380
– – 0.2% 104
2023
Q1
$474K Sell
1,380
-6
-0.4% -$2.02K 0.15% 115
2022
Q4
$507K Sell
1,386
-49
-3% -$17.4K 0.17% 110
2022
Q3
$464K Buy
1,435
+5
+0.3% +$1.58K 0.07% 113
2022
Q2
$464K Hold
1,430
– – 0.16% 119
2022
Q1
$410K Hold
1,430
– – 0.08% 122
2021
Q4
$395K Hold
1,430
– – 0.12% 127
2021
Q3
$330K Buy
1,430
+200
+16% +$49.4K 0.1% 140
2021
Q2
$282K Sell
1,230
-392
-24% -$78.7K 0.1% 153
2021
Q1
$303K Hold
1,622
– – 0.11% 140
2020
Q4
$274K Hold
1,622
– – 0.04% 142
2020
Q3
$240K Buy
+1,622
New +$251K 0.1% 144
2020
Q2
– Sell
-1,380
Closed -$209K – 148
2020
Q1
$209K Buy
+1,380
New +$190K 0.11% 133

Other funds holding LLY

Newman Dignan & Sheerar's LLY Position: Q3 2026 in Review

Newman Dignan & Sheerar held its Eli Lilly (LLY) position steady in Q3 2026 at 1,043 shares worth $1.21M. The position accounts for 0.23% of the portfolio, ranked #80.

Newman Dignan & Sheerar first reported a position in LLY in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.25M in Q2 2026. 4,631 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Newman Dignan & Sheerar held 1,043 shares of Eli Lilly worth $1.21M as of Q3 2026.
  • Newman Dignan & Sheerar left its Eli Lilly share count unchanged in Q3 2026.
  • Eli Lilly made up 0.23% of Newman Dignan & Sheerar's portfolio in Q3 2026, its #80 holding.
  • Newman Dignan & Sheerar first reported a position in Eli Lilly in Q1 2020 and has held it in 26 quarters since.
  • Newman Dignan & Sheerar's Eli Lilly position peaked at $1.25M in Q2 2026.
  • 4,631 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Newman Dignan & Sheerar's 13F filing for Q3 2026, filed 21 Oct 2026.